September 7, 2020
Audrey Jia, Managing Director of Data Revive LLC (a Validant company) will be delivering a Keynote Speech about “Regulatory Challenge from R&D to Marketing for Biological Drugs” during China BioMed Innovation and Investment Conference (CBIIC), which is an annual grand conference to promote the communication between pharmaceutical and investment industry.
By the end of 2019, CBIIC has attracted over 10,000 participants, 2,100 domestic and foreign pharmaceutical enterprises and 1,500 investment institutions, and 33 new drugs made global first clinical trial data release, 450 innovative projects at home and abroad made roadshows in this events, including 80 international projects. CBIIC received extensive attention and was praised as the “most popular cooperation platform for pharmaceutical innovation and investment in Asian-Pacific region”.
Checkout more from: http://cbiic.phirda.com/portal/index/about.html
DataRevive is a leading Regulatory Affairs consulting firm helping pharmaceutical and biotech companies with their regulatory filing of US IND, BLA, and NDA during drug development. DataRevive specializes in both small molecule and biologic product regulatory affairs. They have expertise in CMC (chemistry, manufacturing, controls), nonclinical, clinical pharmacology and clinical areas. Their lead consultants have worked in FDA or industry for more than 18 years with extensive experience in drug discovery and development. For further information, please visit http://www.data-revive.com.